常规药物加心区交感神经阻滞术治疗肥厚型心肌病的临床研究-东南大学学报医学版

常规药物加心区交感神经阻滞术治疗肥厚型心肌病的临床研究

单位：1. 哈尔滨医科大学附属第一临床医学院内科危重症, 黑龙江哈尔滨 150001;
2. 哈尔滨医科大学附属第一临床医学院麻醉科, 黑龙江哈尔滨 150001

分类号：R542.2

出版年·卷·期（页码）：2016·35·第二期（205-207）

摘要：

目的:观察常规药物加心区交感神经阻滞(CSNB)术治疗肥厚型心肌病(HCM)的近期及远期临床疗效。方法:对7例肥厚型心肌病患者行常规药物加CSNB术治疗,比较治疗前后临床症状、NYHA心功能分级、血浆氨基末端脑钠肽前体(NT-proBNP)水平及6 min步行试验距离变化情况,随访6个月内患者再住院率和明尼苏达生活质量评分情况。结果:治疗后患者临床症状明显改善,NYHA心功能分级明显提高,总有效率100%,6 min步行试验距离明显增加(P<0.05),血浆NT-proBNP水平下降。随访6个月,明尼苏达生活质量评分明显下降(P<0.05),再入院率为0。结论:常规药物加心区交感神经阻滞术治疗肥厚型心肌病的近期及远期临床效果好,为肥厚型心肌病治疗提供了新方法。

Objective:To observe the short-term and long-term effect of conventional drugs plus cardiac sympathetic nerve block(CSNB) in treatment of patients with hypertrophic cardiomyopathy(HCM). Methods:Seven patients with HCM were treated with conventional drugs plus CSNB. NYHA heart function classification, plasma NT-proBNP level and the distance change of 6 min walking test were compared before and after treatment. Readmission rate and Minnesota quality of life scale of the patients were followed up 6 months. Results:The clinical symptoms of the patients were significantly improved after treatment. At the time of hospital discharge, the NYHA was obviously improved, the total effective rate was 100%, and the 6 min walk test distance increased(P<0.05) and the plasma NT-proBNP was decreased. After 6 months of follow-up, Minnesota quality of life scale scores decreased significantly(P<0.05), the readmission rate was 0. Conclusion:The short and long-term clinical efficacy of conventional drugs plus CSNB in treatment of HCM is good, which provides a new method for treating HCM.

参考文献：

[1] MARON B J,TOWBIN J A,THIENE G,et al.Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology,Heart Failure and Transplantation Comittee;Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups;and Council on Epidemiology and Prevention[J].Circulation,2006,113(14):1807-1816.
[2] HO C Y.Hypertrophic cardiomyopathy in 2012[J].Circulation,2012,125(11):1432-1438.
[3] 刘凤岐,傅世英,修春红,等.上胸段硬膜外阻滞对扩张型心肌病心腔及收缩功能的影响[J].中华麻醉学杂志,2001,21(3):178-179.
[4] LI Q S,LIU F Q.Effects of thoracic epidural analgesia on plasma cAMP and cGMP levels in patients with heart failure[J].J Cardiothoracic Surg,2013,8:217.
[5] GUO W,LIU F,QU R,et al.Effects of high thoracic epidural sympathetic blockade for the treatment of sever chronic heart failure due to dilated cardiomyopathy[J].Acta Cardiol,2012,67(5):533-539.
[6] PENIKA M,GREGOR P,KEREKES R,et al.The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy:a pilot,randomized study[J].J Mol Diagn,2009,11(1):35-41.
[7] TEEKAKIRIKUL P,EMINAGA S,TOKA O,et al.Cardial fibrosis in mice with hypertrophic cardiomyopathy is mediated by nonmyocyte proliferation and requriea TGF-β[J].J Clin Invest,2010,120(10):3520-3529.
[8] SHAH M R,HASSELBLAD V,GHEORGHIADE M,et al.Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy[J].Am J Cardiol,2001,88(9):987.
[9] 鲁惠.血清NT-proBNP水平与甲状腺功能的相关性研究[J].国际检验医学杂志,2011,32(12):1389-1390.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录